How I treat Langerhans cell histiocytosis, Blood, vol.126, pp.26-35, 2015. ,
Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood, vol.116, pp.1919-1923, 2010. ,
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups, The Journal of Experimental Medicine, vol.211, pp.669-683, 2014. ,
Overview of circulating nucleic acids in plasma/serum, Annals of the New York Academy of Sciences, vol.1137, pp.236-242, 2008. ,
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations, Scientific Reports, vol.5, p.11198, 2015. ,
Analysis of circulating tumor DNA to monitor metastatic breast cancer, New England Journal of Medicine, vol.368, pp.1199-1209, 2013. ,
Liquid biopsies: genotyping circulating tumor DNA, Journal of Clinical Oncology, vol.32, pp.579-586, 2014. ,
A new clinical score for disease activity in Langerhans cell histiocytosis, Pediatric Blood & Cancer, vol.43, pp.770-776, 2004. ,
Salvage Group of the Histiocyte Society. (2015) Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study, Blood, vol.126, pp.1415-1423 ,
Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage, Immunological Reviews, vol.234, pp.213-232, 2010. ,
Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification, Blood, vol.111, pp.2556-2562, 2008. ,
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis, Blood, vol.121, pp.5006-5014, 2013. ,
Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net, Orphanet Journal of Rare Diseases, vol.8, p.72, 2013. ,
Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, Pediatric Blood & Cancer, vol.51, pp.71-75, 2000. ,
URL : https://hal.archives-ouvertes.fr/inserm-00255977
Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years, Pediatric Blood & Cancer, vol.60, pp.175-184, 2013. ,
Vemurafenib use in an infant for high-risk langerhans cell histiocytosis, JAMA Oncology, vol.1, pp.836-838, 2015. ,
BRAF mutation correlates with high-risk langerhans cell histiocytosis and, Journal of Clinical Oncology, vol.34, pp.3023-3030, 2016. ,
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders, Cancer Discovery, vol.5, pp.64-71, 2015. ,
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease, Oncotarget, vol.5, pp.3607-3610, 2014. ,
Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOS-CATO trial, Clinical Cancer Research, vol.22, pp.2960-2968, 2016. ,
Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature, Clinica Chimica Acta, vol.411, pp.1611-1624, 2010. ,
The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis, Blood, vol.124, pp.2610-2611, 2014. ,
Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age, British Journal of Haematology, vol.174, pp.887-898, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01331987
Cell-free nucleic acids as biomarkers in cancer patients, Nature Reviews Cancer, vol.11, pp.426-437, 2011. ,
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clinical Chemistry, vol.59, pp.1722-1731, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299581
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nature Medicine, vol.20, pp.430-435, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02168071